Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and

Stephan H Schirmer1, Joost O Fledderus, Pieter T G Bot

  • 1Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. stephan.schirmer@uks.eu

Circulation Research
|April 19, 2008
PubMed

Insights

Nonresponders to collateral artery growth have higher interferon-beta (IFN-beta) levels, which inhibit smooth muscle cell proliferation and hinder arteriogenesis. Inhibiting IFN-beta signaling may promote new blood vessel growth.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Background:

  • Stimulating collateral artery growth (arteriogenesis) in patients has been unsuccessful.
  • Circulating monocytes play a role in arteriogenesis, but patient responses vary significantly.
  • Understanding transcriptomic differences in monocytes may reveal new therapeutic targets.

Purpose of the Study:

  • To investigate circulating cell transcriptomes for mechanistic insights into arteriogenesis.
  • To identify potential therapeutic strategies to stimulate collateral artery growth.

Main Methods:

  • Measured collateral flow index in 45 patients with coronary artery disease.
  • Isolated and stimulated monocytes from responders and nonresponders.
  • Performed genome-wide mRNA expression analysis and in vitro/in vivo functional assays.

Main Results:

  • Nonresponders showed increased mRNA levels of interferon-beta (IFN-beta) and related genes in stimulated monocytes.
  • IFN-beta dose-dependently inhibited smooth muscle cell proliferation in vitro.
  • IFN-beta treatment attenuated arteriogenesis in a murine hindlimb model.

Conclusions:

  • Differential monocyte transcriptomes correlate with arteriogenic response.
  • Increased IFN-beta signaling in nonresponders hampers collateral artery growth.
  • Inhibiting IFN-beta signaling is a potential therapeutic strategy for stimulating arteriogenesis.